⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 3, 2024

Figure S1 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia

Atham Ali Alvin Phan Vijaya Vaikari Mincheol Park Mateusz Pospiech Ryan Chu Yiting Meng J. Andrew MacKay Houda Alachkar

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S1 – Flow Panels of Annexin and PI staining of U937 Cells following treatment with FLT3-A192, CD99-A192 and Co-Assembled CD99-A192 and FLT3-A192.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ali et al. (2024) studied this question.

synapsesocial.com/papers/68e55ee1e2b3180350efb8ed https://doi.org/10.1158/2767-9764.27157962

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S3 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia2024
2Figure S4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia2024
3Figure 3 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia2024
4Figure S2 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia2024
5Figure 4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia2024